Effects of secondary EGFR mutations on resistance against upfront osimertinib in cells with EGFR-activating mutations in vitro

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) monotherapy is the current standard of care for patients with metastatic or recurrent non-small cell lung cancer (NSCLC) with EGFR-activating mutations. However, the emergence of acquired resistance is almost inevitable after a median period of 9 –13 months [1]. The T790 M secondary mutation [2–4] accounts for about half of resistance to first-generation (1 G) or the 2 G EGFR-TKIs. Osimertinib, a so-called 3 G EGFR-TKI, was developed to inhibit T790 M while sparing wild-type EGFR activity [5].

Source: Lung Cancer - October 30, 2018 Category: Cancer & Oncology Authors: Masaya Nishino, Kenichi Suda, Yoshihisa Kobayashi, Shuta Ohara, Toshio Fujino, Takamasa Koga, Masato Chiba, Masaki Shimoji, Kenji Tomizawa, Toshiki Takemoto, Tetsuya Mitsudomi Source Type: research